黑曲霉菌丝球对直接耐晒翠蓝FBL的脱色特性

探讨黑曲霉(Aspergillus niger)菌丝球的生长特性,以及染料种类对其脱色特性的影响.以直接耐晒翠蓝FBL为处理对象,考察染料初始质量浓度、曲霉孢子投加量、pH值、无机盐质量分数、温度、C源和N源对黑曲霉的脱色性能的影响.结果表明,黑曲霉对多种染料有很好的去除效果.对直接耐晒翠蓝FBL的最佳脱色条件是:染料初始质量浓度低于100 mg.L-1、黑曲霉孢子投加量为2.5×104个.mL-1、染料培养基pH值为6、NaCl质量分数低于5%,培养温度在30~40℃之间,并需适量补充C源、N源

平潭实验区行政主体资格与管理权能的界定

注重制度建设,尤其是法律制度建制,是各种实验区、示范区走向成功的极为重要的条件,也是当前平潭实验区急切的现实需求。平潭实验区面临着行政主体定位不科学、行政管理权限范围模糊、行政管理授权不明等体制局限。平潭实验区的体制创新首先是法律创新问题,只有完善关于平潭实验区的立法,赋予实验区独立行政主体地位,创新有关经济、社会、行政管理等领域的体制机制,走向法治政府,才能使平潭真正发挥两岸交流合作中的“综合实验“作用,实现国家赋予它的历史使命,成为探索两岸交流合作新模式的先行区。厦门大学“985工程”-公共管理重点学科建设项目; 平潭综合实验区行政体制改革方案研究(平潭综合实验区管委会委托项目

Predicting the components and types of kerogen in shale by combining machine learning with NMR spectra

This study aims to develop a new method that combines machine learning with nuclear magnetic resonance (NMR) spectra to predict the kemgen components and types. Kerogen is the primary hydrocarbon source of shale oil/gas, and nearly half of the hydrocarbons in shale are adsorbed in kemgen. The adsorption and hydrocarbon generation capacity of kerogen is directly related to its types, molecular components, and structures. Fruitful researches studying kerogen at the molecular level have been conducted. Unfortunately, these methods are complicated, time-consuming, and labor-intensive. Our method has the advantages of high-throughput prediction, high accuracy, and time savings compared with the existing methods. Additionally, this method simplifies the operations from repetitive trial and error. This study proposes a solution to convert non-uniform two-dimensional (2D) graph into a uniform one-dimensional (1D) matrix, which makes 2D graph data available for machine learning models. An automatic labeling platform is constructed that annotated over 22,000 groups of organic matter molecules and their NMR spectra. The results show that the carbon, hydrogen, and oxygen element prediction accuracy reach 96.1%, 94.8%, and 81.7%, respectively. In addition, the accuracy of the three kerogen types is approximately 90% in total. These results reflect the excellent performance of the machine learning method. Therefore, our work provides an automated and intelligent prediction and analysis method, which is a powerful and superior tool in kerogen studies at the molecular level

ultrasensitivedetectionofhaircortisolbasedonportableramanspectrometeranddoublelayerpapermicrodevice

Cortisol in the human hair is a clinical biomarker of long-term social-and-work-related mental stress, which is of high morbidity rate in the current modern society. This study developed a sensitive hair cortisol assay, featuring surface- enhanced Raman spectroscopy, immunoreaction, and a double-layer paper microdevice. The first layer of the paper microdevice was used to remove the hair residue in the hair extract by filtration (sample pretreatment). The second layer was used for competitive immunoreaction and detection. Standard cortisol antigen immobilized in the second layer and the free cortisol in hair extract competed to bind the spiked Raman-active cortisol monoclonal antibody solution. The hair cortisol can be quantitated by the intensity of Raman signal of monoclonal antibody bound on the paper. We found the Raman signal decreased as the cortisol concentration increases in hair samples. The relative Raman intensity measured was linearly proportional to the logarithmic value of the cortisol concentration in hair samples we measured. The detection of limit (LOD) was 1 pg/mL with the portable Raman spectrometer. The RSD of measurement was 8.38% (n=6). In addition, we used LC-MS to measure two real samples as a comparison with our method as above. The results are 0.771 and 0.153 ng/mL by LC-MS method and 0.63 and 0.247 ng/mL by the proposed method. It can be observed that the results are in same order, demonstrating the validity of the proposed method. In addition, 48 samples can be measured in a single chip. These results showed that this method is sensitive, specific, and suitable for large-scale screening of hair cortisol samples

ultrasensitivedetectionofhaircortisolbasedonportableramanspectrometeranddoublelayerpapermicrodevice

Cortisol in the human hair is a clinical biomarker of long-term social-and-work-related mental stress, which is of high morbidity rate in the current modern society. This study developed a sensitive hair cortisol assay, featuring surface- enhanced Raman spectroscopy, immunoreaction, and a double-layer paper microdevice. The first layer of the paper microdevice was used to remove the hair residue in the hair extract by filtration (sample pretreatment). The second layer was used for competitive immunoreaction and detection. Standard cortisol antigen immobilized in the second layer and the free cortisol in hair extract competed to bind the spiked Raman-active cortisol monoclonal antibody solution. The hair cortisol can be quantitated by the intensity of Raman signal of monoclonal antibody bound on the paper. We found the Raman signal decreased as the cortisol concentration increases in hair samples. The relative Raman intensity measured was linearly proportional to the logarithmic value of the cortisol concentration in hair samples we measured. The detection of limit (LOD) was 1 pg/mL with the portable Raman spectrometer. The RSD of measurement was 8.38% (n=6). In addition, we used LC-MS to measure two real samples as a comparison with our method as above. The results are 0.771 and 0.153 ng/mL by LC-MS method and 0.63 and 0.247 ng/mL by the proposed method. It can be observed that the results are in same order, demonstrating the validity of the proposed method. In addition, 48 samples can be measured in a single chip. These results showed that this method is sensitive, specific, and suitable for large-scale screening of hair cortisol samples

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials